CONNECT: Comparison Of NeuroNaute Smart System to a Standard EleCTroencephalogram System in Hospital

Sponsor
BioSerenity (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT03379272
Collaborator
Pitié-Salpêtrière Hospital (Other)
0
2

Study Details

Study Description

Brief Summary

The proposed study is designed to evaluate the performance of the Neuronaute in comparison with the gold standard EEG in patients with a regular appointment at the hospital. The design of this study is guided by two overriding factors : (i) epileptics disorders suspected or either (ii) epileptics already diagnosed.

Volunteers will be asked to participate to this study. This study will enroll 35 outpatient subjects aged 18 to 85. Informed consent will be obtained from the patients, and assent from the subjects, prior to any form of assessment or intervention as part of the study.

Patients will be submitted to the studied device record Neuronaute following by the gold standard EEG.

A grid with all EEG activity recorded during the trial will be provided for evaluation after completion of the trial.

Condition or Disease Intervention/Treatment Phase
  • Device: GOLDSTANDARD
  • Device: NEURONAUTE
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
CONNECT: Comparison Of NeuroNaute Smart System to a Standard EleCTroencephalogram System in Hospital
Anticipated Study Start Date :
Dec 20, 2020
Anticipated Primary Completion Date :
Dec 20, 2020
Anticipated Study Completion Date :
Dec 20, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: GOLD STANDARD

RECORDING WITH EEG GOLD STANDARD

Device: GOLDSTANDARD
RECORDING WITH EEG GOLDSTANDARD

Experimental: NEURONAUTE

RECORDING WITH THE NEURONAUTE

Device: NEURONAUTE
RECORDING WITH NEURONAUTE

Outcome Measures

Primary Outcome Measures

  1. Reproducibility of electroencephalographic signals interpretation recorded by the Neuronaute compared to the gold standard. [1 year]

    The main evaluation criteria is the reproducibility based on the interpretation of electroencephalographic signals recorded by the Neuronaute compared to the gold standard. The system will be considered effective if there are no significant differences in the physiological parameters recorded by the two systems. A clinical expert will interpret the EEG(electroencephalography) signals and fill the EEG evaluation sheet. It includes items such as signals quality and presence of abnormal events

Secondary Outcome Measures

  1. The Neuronaute will be considered effective if it detects inter-critical epileptic abnormalities in at least one patient. [1 year]

    A section of the evaluation sheet is designed for the secondary objectives.

  2. The Neuronaute will be considered efficient if the installation time is at least as fast as the installation of the gold standard. The time will be measured from the beginning of the patient's preparation until the beginning of the recording. [2 hours]

    The time needed to set up the clinical device and the device under test will be noted in the Case Report Form.

  3. The quality of the Neuronaute's ECG signal will be compared with the gold standard using an evaluation grid. [1 year]

    An evaluation grid led to compare the quality of th Neuronaute's ECG signal and Gold Standard' signal

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients, with a regular appointment to perform an EEG recording: (i) suspected of epileptic disorders or (ii) epilepsy already diagnosed.

  • Age (> 18 years),

  • Affiliated to the social security

  • Informed consent.

Exclusion Criteria:
  • No informed consent

  • Age (< 18 years)

  • No affiliation to the social security

  • Unsuitable anthropometric parameters

  • Pregnant women

  • Recent brain surgery

  • Wound or scores on the body and the scalp

  • Ongoing participation in another clinical trial

  • Allergy to any component from MD including : Silver, polyamide, silicone

  • Sensory disorders making the patient insensitive to pain on the skin

  • Behavioral disorders making the patient excessively agitated or aggressive;

  • Motor or mental disorders preventing the patient from expressing his or her pain;

  • Cardiorespiratory disorders likely to be aggravated by slight compression of the chest;

  • The susceptibility to tension headaches (the compression exerted by the bonnet may in certain cases trigger a headache)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • BioSerenity
  • Pitié-Salpêtrière Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
BioSerenity
ClinicalTrials.gov Identifier:
NCT03379272
Other Study ID Numbers:
  • n°2016-A01754-47
First Posted:
Dec 20, 2017
Last Update Posted:
Nov 11, 2021
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by BioSerenity
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 11, 2021